Literature DB >> 20652717

Effects of growth hormone on bone modeling and remodeling in hypophysectomized young female rats: a bone histomorphometric study.

Lysette Iglesias1, James K Yeh, Mariano Castro-Magana, John F Aloia.   

Abstract

Growth hormone (GH) deficiency causes decreased bone mineral density and osteoporosis, predisposing to fractures. We investigated the mechanism of action of GH on bone modeling and remodeling in hypophysectomized (HX) female rats. Thirty female Sprague-Dawley rats at age 2 months were divided into three groups with 10 rats each: control (CON) group, HX group, and HX + GH (3 mg/kg daily s.c.) group, for a 4-week study. Hypophysectomy resulted in cessation of bone growth and decrease in cancellous bone mass. Periosteal bone formation decreased and bone turnover rate of endocortical and trabecular surfaces increased as compared to the CON group. GH administration for 4 weeks restored weight gain and bone growth and mitigated decrease in bone density after hypophysectomy. However, trabecular bone mass in the proximal tibial metaphysis remained lower in group HX + GH than in group CON. Dynamic histomorphometric analysis showed that bone modeling of periosteal bone formation and growth plate elongation was significantly higher in group HX + GH than in group HX. New bone formed beneath the growth plate was predominately woven bone in group CON and group HX + GH. Bone remodeling and modeling-remodeling mixed modes in the endocortical and PTM sites were enhanced by GH administration; both bone formation and resorption activities were significantly higher than in group HX. In conclusion, GH administration to HX rats reactivated modeling activities in modeling predominant sites and increased new bone formation. GH administration also increases remodeling activities in remodeling predominant sites, giving limited net gain in the bone mass.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20652717     DOI: 10.1007/s00774-010-0210-3

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  38 in total

1.  Effects of separate and combined therapy with growth hormone and parathyroid hormone on lumbar vertebral bone in aged ovariectomized osteopenic rats.

Authors:  L Wang; P B Orhii; J Banu; D N Kalu
Journal:  Bone       Date:  2001-02       Impact factor: 4.398

2.  The effect of short- and long-term growth hormone treatment on bone mineral density and bone metabolism of prepubertal children with idiopathic short stature: a 3-year study.

Authors:  Roberto Lanes; Peter Gunczler; Sara Esaa; Jose R Weisinger
Journal:  Clin Endocrinol (Oxf)       Date:  2002-12       Impact factor: 3.478

3.  Effects of recombinant growth hormone (GH) treatment on bone mineral density and body composition in adults with childhood onset growth hormone deficiency.

Authors:  A Sartorio; S Ortolani; A Conti; R Cherubini; E Galbiati; G Faglia
Journal:  J Endocrinol Invest       Date:  1996-09       Impact factor: 4.256

Review 4.  Growth hormone, insulin-like growth factors and bone remodelling.

Authors:  E F Eriksen; M Kassem; B Langdahl
Journal:  Eur J Clin Invest       Date:  1996-07       Impact factor: 4.686

5.  Effect of vitamin K2 and growth hormone on the long bones in hypophysectomized young rats: a bone histomorphometry study.

Authors:  Jun Iwamoto; Tsuyoshi Takeda; Yoshihiro Sato; James K Yeh
Journal:  J Bone Miner Metab       Date:  2007-01-01       Impact factor: 2.626

Review 6.  Influence of growth hormone on accretion of bone mass.

Authors:  J P Monson; W M Drake; P V Carroll; J U Weaver; J Rodriguez-Arnao; M O Savage
Journal:  Horm Res       Date:  2002

7.  Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.

Authors:  N R Biermasz; N A Hamdy; Y J Janssen; F Roelfsema
Journal:  J Clin Endocrinol Metab       Date:  2001-07       Impact factor: 5.958

8.  Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency.

Authors:  G S Conway; M Szarras-Czapnik; K Racz; A Keller; P Chanson; M Tauber; M Zacharin
Journal:  Eur J Endocrinol       Date:  2009-03-26       Impact factor: 6.664

9.  Growth hormone and parathyroid hormone stimulate intestinal calcium absorption in aged female rats.

Authors:  J C Fleet; M E Bruns; J M Hock; R J Wood
Journal:  Endocrinology       Date:  1994-04       Impact factor: 4.736

10.  Effect of long-term treatment with GH on bone metabolism, bone mineral density and bone elasticity in GH-deficient adults.

Authors:  P Kann; B Piepkorn; B Schehler; J Andreas; J Lotz; W Prellwitz; J Beyer
Journal:  Clin Endocrinol (Oxf)       Date:  1998-05       Impact factor: 3.478

View more
  5 in total

Review 1.  Potential applications for rhIGF-I: Bone disease and IGFI.

Authors:  Marisol Bahamonde; Madhusmita Misra
Journal:  Growth Horm IGF Res       Date:  2020-03-23       Impact factor: 2.372

2.  Growth Hormone and Craniofacial Tissues. An update.

Authors:  George Litsas
Journal:  Open Dent J       Date:  2015-01-30

3.  Effects of chronic sleep deprivation on bone mass and bone metabolism in rats.

Authors:  Xiaowen Xu; Liang Wang; Liying Chen; Tianjiao Su; Yan Zhang; Tiantian Wang; Weifeng Ma; Fan Yang; Wujie Zhai; Yuanyuan Xie; Dan Li; Qiong Chen; Xuemei Fu; Yuanzheng Ma; Yan Zhang
Journal:  J Orthop Surg Res       Date:  2016-08-02       Impact factor: 2.359

4.  Astragalus Extract Mixture HT042 Improves Bone Growth, Mass, and Microarchitecture in Prepubertal Female Rats: A Microcomputed Tomographic Study.

Authors:  Jungbin Song; Sung Hyun Lee; Donghun Lee; Hocheol Kim
Journal:  Evid Based Complement Alternat Med       Date:  2017-05-10       Impact factor: 2.629

Review 5.  The Potential of FGF-2 in Craniofacial Bone Tissue Engineering: A Review.

Authors:  Anita Novais; Eirini Chatzopoulou; Catherine Chaussain; Caroline Gorin
Journal:  Cells       Date:  2021-04-17       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.